Optimized manufacturing of thymus-derived regulatory T cells for immune cell-based therapy

用于基于免疫细胞的治疗的胸腺衍生调节性 T 细胞的优化制造

• 批准号: 404121
• 负责人: MacDonald Katherine N
• 金额: $ 7.65万
• 依托单位: BC Children's Hospital Research Institute
• 依托单位国家: 加拿大
• 项目类别: Studentship Programs
• 财政年份: 2018
• 资助国家: 加拿大
• 起止时间: 2018-10-01 至 2021-10-01
• 项目状态: 已结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=404121&lang=en
• 关键词: Cellular Therapy; Design Of Experiments; Good Manufacturing Practice; Graft-Versus-Host Disease; Hematopoietic Stem Cell Transplant; Human Immunology; Quality By Design; Regulatory T Cell

Blood and bone marrow transplants can be used to treat blood cancers such as leukemia. The transplant can provide a cure when the donor immune cells attack and kill leukemia cells. Unfortunately, the donor cells often also attack the patient's own tissue,

血液和骨髓移植可用于治疗血癌，如白血病。当供体免疫细胞攻击并杀死白血病细胞时，移植可以提供治愈。不幸的是，供体细胞通常也会攻击患者自身的组织，